![]() |
市场调查报告书
商品编码
1403378
安全针全球市场预测(~2030 年):按产品、应用、最终用户和地区进行分析Safety Needles Market Forecasts to 2030 - Global Analysis By Product, Application, End User and By Geography |
2023年全球安全针市场规模为19.7亿美元,预计2030年将达36.7亿美元,预测期内复合年增长率为9.3%。
具有整合安全功能的医用针头称为安全针头。这些设备旨在透过减少与血源性病原体接触的可能性来保护患者和医护人员免受不必要的针刺伤害,并整体提高患者的安全。此外,安全针有多种类型和尺寸可供选择,可为诊所、医院和其他医疗机构的各种医疗任务提供保护。
世界卫生组织预计,由于疫情后政府支出暂时增加,2020年全球卫生支出将飙升至近9兆美元。
患者赋权
赋予患者积极参与医疗保健决策的权利,包括选择安全针头等更安全的医疗设备,是推动安全针头市场的主要因素。患者重视舒适性和安全性,因此他们更喜欢准确、不那么不舒服、不太可能造成针刺伤害的安全针。此外,也鼓励医疗保健提供者采用安全针头解决方案,以满足患者对更安全、更有效的医疗保健体验的渴望。
初期成本高
这些产品的初期成本可能会阻止医疗保健提供者进行投资。此外,儘管与普通针头相比,安全针头由于安全性更高、减少针刺伤害并提高整体医疗保健安全性而通常价格更高,但短期的财务限制可能会阻碍普及。这可能会减缓市场渗透并限制获得更安全的针头选择。
针头安全的技术进步
与智慧型设备和电子健康记录整合等创新功能可改善追踪和合规性。降低针刺风险的针安全技术正在增强病患和医护人员的信心。透过提供减少职场危害的实用解决方案,从而实现更安全的医疗实践。此外,提高安全功能和促进市场成长的监管要求也推动了人们对血源性病原体相关风险的了解不断增加。
缺乏意识
医疗机构和提供者通常不知道安全针头的可用性和好处,这是安全针头市场的缺点。医护人员可能会继续使用普通针头而不考虑风险,从而可能减少安全针头的使用。此外,其他因素包括对安全针的好处和应用的指导和培训不足,这是市场扩张的主要障碍。
安全针市场受到了COVID-19疫情的影响。由于选择性手术和非紧急治疗被取消或推迟,对安全针头的需求减少。全球供应链和製造流程的中断进一步阻碍了这些仪器的生产和分销。此外,由于医疗机构专注于控制感染及其后遗症,安全针头和其他医疗用品受到的关注和资金较少,从而阻碍了该市场的成长。
静脉导管针细分市场预计将成为预测期间最大的细分市场
由于静脉治疗的需求不断增加,并且重点关注减少针刺伤害,静脉导管针段预计将占据最大的市场份额。针锁定机构、易于使用的活化技术和改进的舒适性设计等先进技术经常被用来减少插入和拔除静脉导管期间意外穿刺的可能性。此外,经常使用可伸缩和屏蔽设备来保护患者和医护人员,这推动了这一领域的成长。
预计药物传输领域在预测期内复合年增长率最高
预计药物传输领域在预测期内复合年增长率最高。该领域的创新,例如使用具有内建安全功能的注射器和针头的药物输送系统,使注射药物变得更安全、更方便。这些进展对于需要自我给药的疾病尤其重要,例如糖尿病和自体免疫疾病。此外,不断变化的患者舒适度和安全标准以及医疗保健需求正在促使医疗保健专业人员和患者优先考虑更安全、更有效的药物给药方式,这正在推动该细分市场的成长。
由于为提高工人安全、减少针刺伤数量和阻止血液传播疾病的传播而实施的法规和激励措施,欧洲在预测期内占据了最大的市场占有率。我做到了。该地区是强生、Covidien、Becton、Dickinson & Company 和 Smiths Medical 等主要企业的所在地,这些公司专注于产品创新和技术进步,以满足不断变化的安全标准。此外,安全针具的采用提供了资金、教育和培训计划,从而促进了该地区的成长。
由于医疗保健基础设施的扩张、医疗旅游业的激增以及对医疗保健行业职业安全的日益关注,预计亚太地区在预测期内的复合年增长率最高。印度、日本和中国等国家正在策略性地投资研发,以引进创新的安全针技术。此外,该市场的特点是感染疾病流行日益严重,医疗机构优先透过具有成本效益的安全针头解决方案使用安全设备,这正在推动该地区的成长。我们正在推动。
According to Stratistics MRC, the Global Safety Needles Market is accounted for $1.97 billion in 2023 and is expected to reach $3.67 billion by 2030 growing at a CAGR of 9.3% during the forecast period. Medical needles with integrated safety features are known as safety needles. These devices are intended to shield patients and healthcare personnel against unwanted injuries caused by needle sticks, by lowering the chance of coming into contact with bloodborne pathogens, which improve patient safety in general. Furthermore, various types and sizes of safety needles are available to offer protection throughout a broad range of medical operations in clinics, hospitals, and other healthcare settings.
According to WHO, temporary boosts to government spending caused by the pandemic's aftermath amounted to a surge in global health expenditure close to US$9 trillion in 2020.
Patient empowerment, which involves patients who actively participate in their healthcare decisions, including the selection of safer medical devices like safety needles, is a major factor propelling the market for safety needles. They place a high value on comfort and safety, which makes them favor safety needles, which provide accuracy, less discomfort, and a lower chance of needlestick injuries. Furthermore, healthcare providers have been encouraged to embrace safety needle solutions that correspond with patient desires for safer and more effective healthcare experiences by the market's demand from informed and empowered patients.
The initial cost of these goods might hinder healthcare providers from making an investment. Additionally, compared to regular needles, safety needles are typically more expensive due to their improved safety features, and the uptake may be hampered by the short-term financial restrictions, despite the fact that they reduce needlestick injuries and increase overall healthcare safety; however, compared to regular needles, the cost of fabrication and manufacturing goes up when these safety elements are added. Therefore, this could result in delayed market penetration and restricted access to safer needle options.
Tracking and compliance have increased due to innovative features such as integration with smart devices and electronic health records. Lowering the risk of injuries caused by needles, needle safety technology has increased patient and healthcare staff confidence. This has led to safer medical practices by providing practical solutions to reduce workplace hazards. In addition, increased knowledge of the risks associated with blood borne pathogens had improved safety features and accelerated by regulatory requirements which thereby boosting this market's growth.
Healthcare institutions and providers are frequently unaware of the availability and advantages of safety needles, which is a drawback in the safety needle market. As healthcare workers might continue to use normal needles without thinking about the risks involved, this could lead to a decrease in the use of safety needles. Additionally, another factor contributing is inadequate instruction and training regarding the benefits and application of safety needles, which significantly hampers market expansion.
The safety needle market has been affected as a result of the COVID-19 outbreak. There was a decrease in the necessity for safety needles as elective surgeries and non-emergency treatments were cancelled or postponed. Production and distribution of these devices were further hampered by disruptions in the worldwide supply chain and manufacturing procedures. Furthermore, Safety needles and other medical supplies received less attention and funding as healthcare institutions concentrated on controlling the infection and its after-effects which consequently impeding this market growth.
The IV catheter needles segment is estimated to hold the largest share, due to the growing requirement for intravenous therapy and the emphasis on reducing needlestick injuries. Advancements such as needle locking mechanisms, user-friendly activation techniques, and improved designs for comfort are frequently applied to reduce the possibility of unintentional punctures during the insertion and removal of IV catheters. In addition, they frequently have retractable or shielding devices to protect patients and healthcare personnel, which is boosting this segment expansion.
The drug delivery segment is anticipated to have highest CAGR during the forecast period. Injecting drugs is now safer and more convenient due to innovations in this market area, such as syringes with built-in safety features and needle-based drug delivery systems. These developments are especially important for diseases like diabetes and autoimmune disorders that call for the self-administration of medication. Furthermore, due to changing patient comfort and safety standards as well as changing healthcare needs, healthcare professionals and patients prioritize safer and more efficient means of medicine administration thereby driving this segment growth.
Europe commanded the largest market share during the extrapolated period, owing to regulations and incentives that have been implemented to improve worker safety, lower the number of needles tick injuries, and stop the spread of blood borne illnesses. This region is home to major key players such as Johnson & Johnson, Covidien, Becton, Dickinson & Company, and Smiths Medical, which are focusing on product innovation and technological advancements to meet evolving safety standards. In addition, the adoption of safety needle items offers funding, education, and training programs, which thereby boost this region's growth.
Asia Pacific is expected to witness highest CAGR over the projection period, owing to the expanding healthcare infrastructure, a surge in medical tourism, and an increasing focus on occupational safety in the healthcare sector. Countries including India, Japan, and China are strategically investing in research and development to introduce innovative safety needle technologies. Furthermore, the market is characterized by a growing prevalence of infectious diseases, spurring healthcare facilities to prioritize the use of safety devices with cost-effective safety needle solutions, which are therefore driving this region's expansion.
Some of the key players in the Safety Needles Market include Boston Scientific Corporation, Medtronic, Plc., Smith Medical, Inc., Argon Medical devices, Inc., Terumo Corporation, Becton, Dickinson and Company, Abbott Laboratories, Novo Nordisk A/S, Nipro Medical Corporation, Eli Lily and Company and B. Braun Melsungen AG.
In October 2023, Boston Scientific Corporation announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the WaveWriter Alpha™ Spinal Cord Stimulator (SCS) Systems for the treatment of painful diabetic peripheral neuropathy (DPN), a complication of diabetes that can affect the lower extremities of the body.
In September 2023, Abbott and Bigfoot Biomedical announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes.
In September 2023, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain.
In April 2023, Abbott announced that it has completed the acquisition of Cardiovascular Systems, Inc., a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.